Blood Test Avoidance Creates Major Gaps in Care, HLTH Panel Finds
With 70% of medical decisions depending on lab results, experts highlight the toll of missed testing and the promise of alternative collection methods.
With 70% of medical decisions depending on lab results, experts highlight the toll of missed testing and the promise of alternative collection methods.
The machine learning-powered platform analyzes gene expression data from biopsies to provide molecular scores for rejection probability and tissue injury.
Despite powerful advances in precision medicine, most doctors remain untrained in these emerging diagnostic tools.
The integration is designed to bridge specimen grossing with digital pathology workflows for improved diagnostic accuracy and efficiency.
Researchers say a closer look inside cells could be used by physicians to detect diseases earlier and better match patients to therapies.
The ethyl alcohol assay categorization enables moderate complexity laboratories to expand drug screening capabilities on the Abbott analyzer platform.
The infrared dye antibody conjugates aim to expand human phenotyping experiments innovation and make high-parameter flow cytometry more accessible.
The DX-60 system offers 28 reportable parameters, malaria detection capabilities, and requires minimal sample volumes for testing.
Market growth driven by expanding clinical applications and regulatory innovation, with kits and reagents dominating product segments.
New instrument features StreamFocus ionization technology and AI-powered intelligence for enhanced sensitivity and efficiency in clinical laboratories.
Research-use-only assay identifies 28 urinary targets and 25 antibiotic resistance markers with same-day turnaround time.
New materials aim to help patients and providers understand emerging molecular diagnostic tools for hypertensive disorders of pregnancy.
The CLIA-waived immunoassay delivers results in as fast as 10 minutes and is designed for physician offices, urgent care centers, and decentralized hospital labs.
The sharp increase in fentanyl in random drug checks suggests more workers are using the opioid after they have passed pre-employment screens.